Evaluation of Prevalence of ventricular tachyarrhythmia in patients with acute myocardial infarction and serum magnesium in Khatam-Al-Anbia Hospital, Zahedan, Iran

Loading...
Thumbnail Image

Journal Title

Journal ISSN

Volume Title

Publisher

Brieflands

Abstract

Background: To establish between hypomagnesemia and predicts excessive morbidity, particularly ventricular tachyarrythmias in patients with acute myocardial infarction (AMI). Method and Materials: A case control study was designed over one year period in 200 patients with AMI (100 patients with ventricular tachyarrythmias and 100 patients without arrythmias) whose admitted to a coronary care unite of khatam hospital of zahedan. For all of them serum magnesium concentration was measured first and 12 hours later during 24h after AMI the patient’s rhythm was continously recorded. The main study parameters were occurance of ventricular tachyarythmias and lts relationship with hypomagnesemia. Results: From 100 patients with AMI and ventricular tachyarrythmias mean ages were 57/2±12/9 (p=0/36) and first serum magnesium was 1/9 ± 0/46 (p=0/051) and second serum magnesium was 2± 0/32 (p=0/003) and %55 of patients were male that from those patients due to first serum magnesium 39 patients were hypomagnesemic, OR=2/4 and due to second serum magnesium 36 patients were hypomagnesemic, OR= 10/7 and from 100 patients with AMI without ventricular tachyarrythmias mean ages were 58/9 ± 12/3 (p=0/36) and first serum magnesium 2± 0/28 (p=0/051) and second serum magnesium 2/1± 0/18 (p=0/003) and %45 of patients were male that from those patients due to first serum magnesium 21 patients were hypomagnesemic and due to second serum mognesium only 5 patient were hypomagnesemic. Conclusions: In this study we conclude that hypomagnesemia due to first serum magnesium can increase 2/4 fold ventricular tachyarrythmias and due to second serum magnesium can Increase 10/7 fold.Thus hypomagnesemia can be a major risck factor for ventricular tachyarrythmias after AMI and immediate diagnosis and treatment of hypomanesemid can reduce morbidity and mortality after AMI. Thus we recommended that for any patients with AMI serum magnesium must be measured at admission to CCU and initiate proper treatment for hypomagnesemia

Description

Keywords

Citation

URI

Endorsement

Review

Supplemented By

Referenced By